Dried Reconstituted Vesicles for Protein Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing liposomes, particularly for large-scale manufacturing of protein encapsulation, face challenges such as low encapsulation efficiency, stability issues, and the need for harsh freeze-thaw cycles, which can lead to protein degradation and instability during storage and handling.
Innovation Solution
A method involving the use of freeze-dried liposomes with a fusion promoting agent, such as alkaline amino acids, that form multilamellar liposomes upon rehydration, avoiding the need for membrane stabilizing agents and harsh freeze-thaw cycles, resulting in high encapsulation efficiency and stability of hydrophilic proteins like CD-RAP for applications in bone and cartilage regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional liposome preparation methods are used, then liposomes can be formed, but encapsulation efficiency is low and stability during storage is poor
Solution Approach 1:
The patent applies preliminary action by forming liposomes before dehydration and freeze-drying them in a lyophilized state. This pre-formed liposome structure maintains its integrity through storage and can be reconstituted later, achieving both high encapsulation efficiency during formation and storage stability in dried state. The liposomes are prepared with therapeutic agents encapsulated, then dehydrated to a stable powder form that can be stored without degradation.
Solution Approach 2:
The patent utilizes parameter changes by transitioning the liposome formulation from hydrated to dehydrated state through controlled freeze-drying. This parameter change (moisture content) allows the liposomes to maintain structural integrity during storage while enabling high encapsulation efficiency. The freeze-drying process removes water to create a stable, shelf-ready product that can be reconstituted when needed.
2Manufacturing precision
If freeze-thaw cycles are used to form multilamellar vesicles, then encapsulation can be achieved, but protein degradation occurs due to harsh physical manipulation
Solution Approach 1:
The patent extracts or removes the harmful freeze-thaw cycling step from the traditional multilamellar vesicle formation process. Instead of using repeated freezing and thawing cycles that degrade proteins, the invention forms liposomes in a single step and then dehydrates them. This eliminates the mechanical stress and thermal shock that cause protein degradation while maintaining encapsulation efficacy.
Solution Approach 2:
The patent replaces the mechanical freeze-thaw system with a chemical/dehydration-based approach. Instead of using temperature cycling to drive vesicle formation, the invention uses controlled dehydration through freeze-drying to achieve the same encapsulation result without the harmful mechanical manipulation. This substitution preserves protein integrity while achieving multilamellar structure formation.
3Reliability
If membrane stabilizing agents are added to preserve liposomes during dehydration, then stability improves, but the complexity of the formulation increases
Solution Approach 1:
The patent applies self-service by allowing the liposome membrane to stabilize itself during dehydration without requiring additional membrane stabilizing agents. The natural lipid composition and structure of the liposomes provide inherent stability during the freeze-drying process. This self-stabilization capability eliminates the need for extra formulation components, maintaining simplicity while achieving storage stability.
4Object-affected harmful factors
If small liposomes are used for parenteral application, then embolism risk is reduced, but encapsulation efficiency and sustained release capability decrease
Solution Approach 1:
The patent applies preliminary action by forming large multilamellar liposomes with high encapsulation efficiency before administration. These liposomes are prepared in advance with therapeutic agents encapsulated, then dehydrated for stable storage. When reconstituted and administered, they provide sustained release without causing embolism because their large size and multilamellar structure enable controlled drug release over time rather than immediate systemic distribution.
Solution Approach 2:
The patent utilizes the nested doll principle through multilamellar structure where multiple lipid bilayers are nested concentrically with aqueous compartments between them. This nested structure allows efficient encapsulation of therapeutic agents in the internal aqueous phases while the multiple layers provide controlled release. The nested configuration maximizes encapsulation volume while maintaining a structure suitable for parenteral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of stable, large multilamellar liposomes with high encapsulation efficacy, providing prolonged release of proteins and improved stability, suitable for treating conditions like osteoarthritis and bone diseases, with enhanced retention and efficacy at the site of application.
Implementation Method 1
attempts to increase short storage life of a liposomal formulation by dehydration have been the focus of several preparation methods
Implementation Method 2
When the solution is dried to a highly viscous lipid mixture, the individual liposomes fuse to form MLVs, which encapsulate the active agent between the lamellae. Upon rehydration, lipid vesicles form, in which the material is encapsulated.
Data Source
Figure 1A~1B
Figure 2A~2D
Figure 3
AI summary
The present invention relates to dried reconstituted vesicle (DRV) compositions and water based formulations thereof, which contain one or more therapeutic agents (e.g. hydrophilic protein). More particularly, it relates to DRVs comprising at least one lipid and a fusion promoting agent which after reconstitution form large multilamellar liposomes encapsulating an active agent in an aqueous phase.